Oncotarget

Research Papers:

CXCR1/2 pathways in paclitaxel-induced neuropathic pain

Brandolini Laura, Benedetti Elisabetta, Ruffini Pier Adelchi, Russo Roberto, Cristiano Loredana, Antonosante Andrea, d’Angelo Michele, Castelli Vanessa, Giordano Antonio, Allegretti Marcello _ and Cimini Annamaria

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:23188-23201. https://doi.org/10.18632/oncotarget.15533

Metrics: PDF 1532 views  |   HTML 1765 views  |   ?  


Abstract

Brandolini Laura1,*, Benedetti Elisabetta2,*, Ruffini Pier Adelchi3, Russo Roberto4, Cristiano Loredana2, Antonosante Andrea2, d’Angelo Michele2, Castelli Vanessa2, Giordano Antonio5,6, Allegretti Marcello1, Cimini Annamaria2,6,7

1Dompé Farmaceutici SpA, Via Campo di Pile, L’Aquila, Italy

2Department of Life, Health and Environmental Sciences, University of L’Aquila, Italy

3Dompé Farmaceutici SpA, Via Santa Lucia, Milano, Italy

4Department of Pharmacy, University of Naples Federico II, Italy

5Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

6Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, Temple University, Philadelphia, USA

7National Institute for Nuclear Physics (INFN), Gran Sasso National Laboratory (LNGS), Assergi, Italy

*These authors contributed equally to this work

Correspondence to:

Allegretti Marcello, email: marcello.allegretti@dompe.com

Keywords: chronic pain, chemotherapy, microtubules, IL-8, CXCR1/2 inhibitor

Received: January 04, 2017     Accepted: February 08, 2017     Published: February 20, 2017

ABSTRACT

Chemotherapy-induced peripheral neuropathy (CIPN) is a type of neuropathic pain that represents a frequent and serious consequence of chemotherapy agents. Over the last years, significant progress has been achieved in elucidating the underlying pathogenesis of CIPN. The interference of taxanes with microtubule has been proposed as a mechanism that leads to altered axonal transport and to permanent neurological damages. The inflammatory process activated by chemotherapeutic agents has been considered as a potential trigger of nociceptive process in CIPN.

In this study we investigated the effect of reparixin, an inhibitor of CXCR1/CXCR2, in suppressing the development of paclitaxel-induced nociception in rats. Moreover, reparixin activity in reversing the neurotoxic effects induced by paclitaxel or GRO/KC in F11 cells was also analyzed.

Reparixin administered by continuous infusion ameliorated paclitaxel-induced mechanical and cold allodynia in rats. In F11 cells, reparixin was able to inhibit the increase of acetyladed α-tubulin induced both by paclitaxel and GRO/KC. The subsequent experiments were performed in order to dissect the signal transduction pathways under GRO/KC control, eventually modulated by paclitaxel and/or reparixin. To this aim we found that reparixin significantly counteracted p-FAK, p-JAK2/p-STAT3, and PI3K-p-cortactin activation induced either by paclitaxel or GRO/KC.

Overall the present results have identified IL-8/CXCR1/2 pathway as a mechanism involved in paclitaxel-induced peripheral neuropathy. In particular, the obtained data suggest that the inhibition of CXCR1/2 combined with standard taxane therapy, in addition to potentiating the taxane anti-tumor activity can reduce chemotherapy-induced neurotoxicity, thus giving some insight for the development of novel treatments.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15533